BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11071711)

  • 1. Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay.
    Xu H; Hashimoto A; Rice KC; Jacobson AE; Thomas JB; Carroll FI; Lai J; Rothman RB
    Synapse; 2001 Jan; 39(1):64-9. PubMed ID: 11071711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid peptide receptor studies. 15. Relative efficacy of 4-[(N-allyl-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human delta-opioid receptor.
    Xu H; Lu YF; Thomas JB; Carroll FI; Rice KC; Rothman RB
    Synapse; 2001 Jun; 40(4):269-74. PubMed ID: 11309842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
    Selley DE; Liu Q; Childers SR
    J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor.
    Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB
    Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor.
    Xu H; Lu YF; Rothman RB
    Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
    Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
    Zhao GM; Qian X; Schiller PW; Szeto HH
    J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands.
    Xu H; Lu YF; Partilla JS; Zheng QX; Wang JB; Brine GA; Carroll FI; Rice KC; Chen KX; Chi ZQ; Rothman RB
    Synapse; 1999 Apr; 32(1):23-8. PubMed ID: 10188634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
    Xu H; Wang X; Wang J; Rothman RB
    Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
    Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
    Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.